General Topics
Eden Spine announced today that it has received CE Mark approval for its proprietary interspinous medical device, the WellexT. Developed in collaboration with Dr. Jean-Marc Fuentes from France, the Wellex is based on two decades of clinical experience with nonfusion devices. "The Wellex is a compressible dynamic extension controller that not only relieves pain but also positively affects the long-term health of the segment," said Dr.
Researchers at the Indiana University Melvin and Bren Simon Cancer Center are conducting a novel clinical trial that may reverse the resistance that frequently develops to the most common drug for treating recurrent ovarian cancer. Over time, many ovarian cancer patients can become resistant to the drug carboplatin, which is the best treatment option for recurrent disease. Daniela Matei, M.D.
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), announced that it has commenced a Phase IIb efficacy study for AVR123 in wound healing. The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen Germany, led by Eckhart Kampgen, M.D., Associate Professor for Strategies of Cellular Immunotherapy at the Department of Dermatology. Dr.
According to Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization, the world is getting better, no matter what critics say.
(613) 686-5745 Cerepotec Pharmalef
MEDISON Co., Ltd, a world leader in 3D/4D ultrasound systems and the first to develop and commercialize 3D ultrasound image technology, plans a global launch of its new ACCUVIX V20 model in the second half of this year.. The technology-intensive new product was showcased at major international conferences and exhibitions, starting with the International Society of Ultrasound in Obstetric and Gynecology 2008 in Chicago in August.
Cerimon Pharmaceuticals, Inc., announced it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients.
Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, submitted to the FDA a pre-IDE (Investigational Device Exemption) protocol for a clinical study using Biomoda's proprietary assay for detection of early lung cancer in veterans. The New Mexico state legislature allocated more than $1.
It is an undesirable reality, but the development of pharmaceutical drugs is a costly undertaking. Yet, these costs are necessitated by the substantial investment of both time and resources of the companies in question. It stands to reason that if a company is willing to invest millions of dollars that they would seek individuals and companies that had the professionals, resources, and capacity to minimize overhead costs and the time needed to bring a drug to the market.
(613) 686-5745 Cerepotec Pharmalef
Due to patient complexity, the practice environment, and the lifestyle, medical students are becoming increasingly less likely to choose internal medicine as a career specialty. These findings are published in the medical education-themed September 10 issue of JAMA. Much of the chronic care for older and medically complex patients is provided by internists in primary care and subspecialty practice.
Mobile Doctors announces new dates for its 'Excellence in Report Writing' training in response to demand from GPs and specialists. Mobile Doctors, one of the UK's leading providers of medical evidence, is pleased to announce a host of new dates for its 'Excellence in Report Writing' courses, which provide training to General Practitioners (GPs) and specialists in how to compile medico-legal reports and give evidence in court.
The U.S. Food and Drug Administration recommended today that manufacturers developing new drugs and biologics for type 2 diabetes provide evidence that the therapy will not increase the risk of such cardiovascular events as a heart attack. The recommendation is part of a new guidance for industry that applies to all diabetes drugs currently under development. "We need to better understand the safety of new antidiabetic drugs.
The Clinical Research Organization industry has reached a new level of development in clinical trials. There are now more than twelve hundred CROs with the greatest number existing in Europe, followed by North America and Asia.
(613) 686-5745 Cerepotec Pharmalef
Researchers at the National Institute of Standards and Technology (NIST) and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer's disease actually impairs a neuron's structure and function. The team's findings are reported in a new paper in the Biophysical Journal.
Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company is tentatively scheduled to meet with the U.S. Food and Drug Administration (FDA) during the week of Oct. 20, 2008 to discuss any remaining issues that the agency has about the use of Oxycyte® in a proposed Phase IIb clinical trial in Traumatic Brain Injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. The meeting date and time are subject to final confirmation by the agency.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the initiation of the Community Acquired Pneumonia Immunization Trial in Adults a major study in adults of an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia -- the leading cause of bacterial pneumonia in adults.
The clinical research industries growth is skyrocketing, the portion of the market outsourced to CROs is said to have grown from US$1 billion dollars in the early 1990’s to over US$17 billion in 2007.
(613) 686-5745 Cerepotec Pharmalef
The majority of physicians practicing in Canada have gone through a similar education and examination process. Following an undergraduate experience outside of medicine (and for some, advanced degrees), completion of a four-year undergraduate medical education at an accredited Canadian faculty of medicine leads to the degree of Medical Doctor, the MD.
The Russian regulatory body has approved YONDELIS® (trabectedin) for the treatment of soft tissue sarcoma in adults. This represents another approval for YONDELIS® for treatment soft tissue sarcoma (STS) following upon its approval in Europe in September 2007, which opens up new opportunities in markets with enormous growth potential. Under the licensing agreement with Ortho Biotech Products, L.P., PharmaMar will receive royalties on sales of YONDELIS® in Russia.
The European Commission adopted today the so-called "pharma package", which consists of a Communication covering "a renewed vision for the pharmaceutical sector" and legislative proposals on information to patients, falsified medicines and pharmacovigilance. "This package well recognises the particularities of non-prescription medicines", stated AESGP (Association of the European Self-Medican Industry) Director General Hubertus Cranz.
CROs were first organized as outsourcing service companies that provided only clinical trial management. Today, many CROs have expanded their scope of services to provide comprehensive management of the complex drug trial processe
(613) 686-5745 Cerepotec Pharmalef
Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated
www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.
One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.
Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.
This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.
Cereprotec Inc.
www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.
At this moment Cereprotec Inc.
www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.
In Phase II Cereprotec Inc.
www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated
www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.
This company is also developing a family of other promising novel chemical compounds.
Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.
Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation")
www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc.
www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.
Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.
Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.
Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments .
www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.
In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
Pharmalef Developments
www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments
www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.
They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.
They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008
A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/200802278381. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.
3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.
4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.
5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.
6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.
7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.
8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.
9. The method according to claim 8, wherein said head trauma injury is closed head injury.
10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.
11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.
12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.
13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.
14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.
15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.
16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.
17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.
18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.
19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.
20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.
21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
Medical Training
Springer editor Geoffrey R. Norman is this year's winner of the Karolinska Institutet Prize for Research in Medical Education. He has been singled out for his highly original and innovative research in the field of medical education.
AFMC (The Association of Faculties of Medicine of Canada) President and CEO Nick Busing, M.D., issued the following statement today urging the Canadian Government to follow the lead of US Senate Democratic leaders by increasing funding for the Canadian Institutes of Health Research as a strategy for economic prosperity.
When academic articles are "open access" or free online, they get read more often, but they don't -- going against conventional wisdom -- get cited more often in academic literature, finds a new Cornell study. The reason, suggest Cornell graduate student Philip Davis and colleagues, including three Cornell professors, is that most researchers probably already have all the access they need to relevant articles.
As a drug makes its way through the different phases of pre-clinical and clinical trials in human testing, the public and the company can rest assured that their product has been thoroughly tested and that each...
(613) 686-5745 Cerepotec Pharmalef
Our Kid: Medical Manchester, 1948 - 2008 22 October - 29 November 2008 The foyer at Manchester Central Library A larger than life size figure is set to reveal the dramatic changes in Manchester's medical history like never before. A new installation, with a multi-media exhibition at its heart, traces the regions past medical breakthroughs and blows the lid on what healthcare could be like in the future.
Two newspapers recently published two editorials and an opinion piece about recent recommendations by an Institute of Medicine committee that medical residents who work a 30-hour shift should have a five-hour, uninterrupted break to sleep after they have worked 16 hours. Summaries appear below.
The NPA Education and Training Department is now taking bookings for the Preregistration Trainee Pharmacist Training Programme 2008/2009. The programme covers key components of the syllabus as well as those elements that are difficult to cover in the pharmacy (e.g. First Aid Training). Candidates will have a choice of three venues for the study courses: Wakefield, Birmingham and St Albans.
Anestvice ( www.anestvice.com )Pressure Controller (APC) – device for maintaining of precisely set pressure in the cuff of Laryngeal Mask (LM) and Endotracheal Tube (ETT) during the surgery...
(613) 686-5745 Cerepotec Pharmalef
December 5th-7th sees the 10th Mountain Medicine and High Altitude Physiology Course, set in the dramatic scenery of Plas Y Brenin, the National Mountain Centre in Capel Curig, Gwynedd, North Wales. Run by the University of Leicester in association with Medical Expeditions, the three-day course attracts an international panel of speakers, including leading altitude physiologists and physicians from around the world.
Despite performing equally to their male peers in the classroom and the clinic, female medical students consistently report decreased self-confidence and increased anxiety, particularly over issues related to their competency. A new study published in the September 2008 issue of
Among the undergraduate offerings Yale University is making freely available by Internet access through the Open Yale Courses are three popular science courses in biomedical engineering, physics and astronomy. "Frontiers of Biomedical Engineering," taught by professor W. Mark Saltzman, is newly added to the initial offerings of "Frontiers and Controversies in Astrophysics" by professor Charles Bailyn and "Fundamentals of Physics" by professor Ramamurti Shankar.
The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.
(613) 686-5745 Cerepotec Pharmalef
The Royal Australian College of General Practitioners (RACGP) has launched a new online learning module to support general practitioners, practice nurses and general practice managers in the delivery of palliative care in aged care homes. These activities have been developed by Palliative Care Australia, with funding from the Australian Government Department of Health and Ageing.
Researchers from Boston Medical Center (BMC) have found that education on addiction is inadequate during medical training, resulting in suboptimal medical care for those at risk. However, the research also found that a Chief Resident Immersion Training (CRIT) program in addiction medicine is an effective "train the trainers" model for dissemination of addiction knowledge and skills to generalist physician trainees. These findings appear in the Journal of General Internal Medicine.
Academic health centers (AHCs) have a critical role in enabling, encouraging, and rewarding the sharing of biomedical research data, say a team of academics in this week's PLoS Medicine. "The leaders of medical schools and academic-affiliated hospitals," they say "can play a unique role in supporting this transformation of the research enterprise.
As per Bruce Kriger, CEO of Kriger Research Group International www.kriger.com , leading training institution and clinical research organization, Good Clinical Practice Guidelines is a general document used by various clinical research professionals who perform different functions in clinical research.
(613) 686-5745 Cerepotec Pharmalef
There is now a "once in a generation" opportunity to get sensible plans in place for health care over the next 20 years, according to an article in the latest issue of the Medical Journal of Australia.
The selection of students for entry to medical schools in Australia is a high-stakes contest. A recent study reported in the latest issue of the Medical Journal of Australia showed that more than half the applicants trying to gain a place at an Australian medical school had attended coaching, and some had repeated selection tests, in order to boost their chances of admission.
Pfizer officials recently announced that the company will no longer provide direct financial support for continuing medical education courses offered by for-profit medical education and communication companies, the Wall Street Journal reports.
The process of clinical trials can be costly to say the least. Clinical affairs consumes an average of 37% of R&D budgets.
(613) 686-5745 Cerepotec Pharmalef
Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated
www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.
One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.
Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.
This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.
Cereprotec Inc.
www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.
At this moment Cereprotec Inc.
www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.
In Phase II Cereprotec Inc.
www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated
www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.
This company is also developing a family of other promising novel chemical compounds.
Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.
Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation")
www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc.
www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.
Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.
Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.
Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments .
www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.
In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
Pharmalef Developments
www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments
www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.
They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.
They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008
A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/200802278381. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.
3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.
4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.
5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.
6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.
7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.
8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.
9. The method according to claim 8, wherein said head trauma injury is closed head injury.
10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.
11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.
12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.
13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.
14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.
15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.
16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.
17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.
18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.
19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.
20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.
21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
Medical Devices
An online advertising service that will help 'hook up' NHS providers with healthcare suppliers was announced today by Health Minister Ben Bradshaw.
Neuronetics, Inc., a privately-held medical device company and a leader in the field of neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has cleared its NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy system for the treatment of depression.
Delivers powerful combination of the highest sensitivity in the industry, next generation of MotionFree technology, high definition imaging, fast reconstruction with the IBM BladeCenter® Continuing its leadership in PET/CT technology, GE Healthcare announced the introduction of D
Limdato, www.limdato.com knows that you will never see effective monitoring results unless you know the “red flag” issues in your trial.
(613) 686-5745 Cerepotec Pharmalef
Researchers have demonstrated a new instrument that makes it possible to detect and quantify multiple different clinically important proteins in a single tumor sample using conventional staining. Currently, pathologists usually need a separate tissue slice for each protein they want to examine, making it impossible to see how molecules interact within individual cells.
MED-EL Corporation has announced new data regarding FineHearingTM technology, available only with the MAESTROT Cochlear Implant System. In addition to hearing in "high definition" with FineHearing, MED-EL's MAESTRO system offers the smallest internal implant and the thinnest, lightest externally-worn speech processor available.
The National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH), announced today that it will provide $33.3 million for 20 High-End Instrumentation (HEI) grants to fund the latest generation of advanced research equipment.
Several Kriger www.krigerinternational.com course sessions are dedicated to understanding concepts and principles that have helped mold the industry into what it is today. This gives each student the opportunity to understand how the industry is progressing...
(613) 686-5745 Cerepotec Pharmalef
Today, October 1, 2008, the Manhattan Institute's Center for Medical Progress announces the launch of Project FDA. Project FDA is an initiative designed to help the Food and Drug Administration develop the 21st Century technologies and regulations that can accelerate medical innovation, and get safer and more effective treatments to patients faster, cheaper, and smarter than is currently possible.
Playing Pinball with Atoms With nanotechnology yielding a burgeoning menagerie of microscopic pumps, motors, and other machines for potential use in medicine and industry, here is one good question: How will humans turn those devices on and off? In an advance toward giving humans that control, scientists in The Netherlands are reporting use of an external electrical signal to control an atomic-scale mechanical device that looks like the flippers on a pinball machine.
Hitachi Europe Ltd, Display Products Group (DPG) has announced the introduction of a new 19inch 1.7MegaPixel WSXGA+ TFT display module. The new TX48D21VM0CAA display implements the latest evolution of Hitachi's In-Plane-Switching technology, IPS-Pro, which provides a stable colour image from any viewing angle, excellent colour saturation and a very high contrast ratio.
As per ClinQua Inc. www.clinqua.com relationships exist on all levels of clinical development. Primarily, problems arise when there are fundamental breakdowns in the delegation of responsibilities or rather when someone is given control over a critical area when they are otherwise unqualified.
(613) 686-5745 Cerepotec Pharmalef
Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). The payoff for successful molecular diagnostic products can be significant as Kalorama Information predicts that this market currently exceeds $3.2 billion worldwide and will reach $5.4 billion in four years, according to an article in the October 1 issue of GEN.
A University of Colorado at Boulder study of a space-age, low-gravity training machine used by several 2008 Olympic runners showed it reduced impacts on muscles and joints by nearly half when subjects ran at the equivalent of 50 percent of their body weight.
MiCardia Corporation announced that the U.S. Food and Drug Administration ("FDA") has granted 510(k) marketing clearance for its DynaplastyT Annuloplasty Band DRT and Annuloplasty Ring DR. These are the first of MiCardia's innovative Dynaplasty Technology products to receive clearance.
Kriger Research Group International www.krigerclinical.com provides clinical research services for pharmaceutical and biotechnology product development from phase II through phase IV for US, Canadian, European and multinational pharmaceutical companies. KRGI is your way to high quality design, conduct and analysis of clinical trials.
(613) 686-5745 Cerepotec Pharmalef
In the budding field of nanotechnology, scientists already know that size does matter. But now, researchers at the University of North Carolina at Chapel Hill have shown that shape matters even more - a finding that could lead to new and more effective methods for treating cancer and other diseases, from diabetes and multiple sclerosis to arthritis and obesity. A team of researchers led by Joseph DeSimone, Ph.D.
Ascension Technology Corporation has shrunk the dimensions of its 3D Guidance medSAFE magnetic sensor without sacrificing tracking parameters. The outer diameter of its new sensor is 0.90 mm (0.035 inch), small enough to comfortably fit the hollow tube of a 19-gauge biopsy needle. The new sensor passively senses pulsed DC magnetic fields generated by either a cubic transmitter or a flat transmitter and is available for easy integration and manufacturability by medical OEMs.
Building on its reputation for excellence in the deliverability of its angioplasty products, Medtronic, Inc. (NYSE: MDT), announced the U.S. market launch of the Endeavor Sprint drug-eluting stent (DES) on a rapid exchange (RX) delivery system.
Typically, large CROs compete on the basis of medical and scientific expertise in specific therapeutic areas; the ability to manage large-scale trials on a global basis with strategically located facilities
(613) 686-5745 Cerepotec Pharmalef
Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated
www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.
One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.
Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.
This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.
Cereprotec Inc.
www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.
At this moment Cereprotec Inc.
www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.
In Phase II Cereprotec Inc.
www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated
www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.
This company is also developing a family of other promising novel chemical compounds.
Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.
Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation")
www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc.
www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.
Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.
Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.
Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments .
www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.
In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
Pharmalef Developments
www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments
www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.
They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.
They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008
A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/200802278381. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.
3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.
4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.
5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.
6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.
7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.
8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.
9. The method according to claim 8, wherein said head trauma injury is closed head injury.
10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.
11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.
12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.
13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.
14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.
15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.
16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.
17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.
18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.
19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.
20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.
21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.